Finally, reimbursement discussions for the new neurofibromatosis drug ‘Koselugo’ has made some progress.

Results showed that AstraZeneca Korea’s new neurofibromatosis drug has passed the review by the Health Insurance Review and Assessment Service’s Drug Reimbursement Standard Subcommittee recently. Therefore, its reimbursement can now be deliberated by the Drug Reimbursement Evaluation Committee.

After the drug received a non-reimbursement decision from DREC in March, the company worked promptly and prepared the supplementary data to restart listing discussions for the drug.

As NF1 is a rare disease area with no available treatment option, whether Koselugao will be